Core Viewpoint - The patent dispute between two listed pharmaceutical companies, Huadong Medicine and Zhaoli Pharmaceutical, centers on the ownership of the invention patent for fermented Cordyceps sinensis powder, which is a key ingredient in the Bailing capsule product line. The competition is intensifying as Zhaoli Pharmaceutical's Bailing capsule has been approved, breaking Huadong Medicine's previous monopoly in this market segment [3][5][10]. Group 1: Patent Dispute Details - Huadong Medicine's Bailing capsule previously generated annual sales exceeding 3 billion yuan, and the core ingredient is fermented Cordyceps sinensis powder [3][11]. - Huadong Medicine filed a lawsuit against Zhaoli Pharmaceutical and its subsidiaries, claiming patent infringement and seeking approximately 1.11 billion yuan in damages [5][6]. - The Zhejiang High Court ruled against Huadong Medicine in the first instance, dismissing all claims and ordering it to bear over 590,000 yuan in court fees [7][8]. Group 2: Market Impact and Financial Performance - The Bailing series, which includes Bailing capsules, Bailing granules, and Bailing tablets, is a significant market segment, with both companies nearly splitting the market [10][11]. - Huadong Medicine's Bailing capsule sales peaked at 3.486 billion yuan in 2019, but sales have since declined to around 1.8 billion yuan in 2022 due to price reductions [11][12]. - Zhaoli Pharmaceutical's Bailing tablet series generated 2.02 billion yuan in revenue in 2023, reflecting a 21.23% decline from the previous year due to competitive pressures [12][13]. Group 3: Future Prospects - Zhaoli Pharmaceutical aims to develop the Bailing series into a 1 billion yuan product line, indicating strong growth ambitions [15]. - The Bailing series, including both Bailing tablets and capsules, contributed 1.13 billion yuan in revenue in the first half of 2025, marking a 38.51% increase year-on-year [14]. - As of December 16, the market capitalization of Huadong Medicine was approximately 69.1 billion yuan, while Zhaoli Pharmaceutical's market cap was around 11.9 billion yuan [16].

Core Viewpoint - The article discusses the patent dispute between two listed pharmaceutical companies, Huadong Medicine and Zhaoli Pharmaceutical, focusing on the core ingredient of the Bailing capsule, which has historically generated significant sales revenue for Huadong Medicine [5][8]. Group 1: Patent Dispute Details - The lawsuit centers on the patent rights of fermented Cordyceps sinensis powder, which is the main ingredient in the Bailing capsule, previously a unique product for Huadong Medicine with annual sales exceeding 3 billion yuan [8][12]. - Huadong Medicine filed a lawsuit against Zhaoli Pharmaceutical and its subsidiaries, claiming infringement of its patent rights and seeking approximately 1.11 billion yuan in damages [11][12]. - The Zhejiang High Court ruled against Huadong Medicine in the first instance, dismissing all claims and ordering it to bear over 590,000 yuan in court fees [13][14]. Group 2: Market Competition - The competition between Huadong Medicine and Zhaoli Pharmaceutical is intensifying, with both companies nearly splitting the market for Bailing products [8][17]. - Huadong Medicine's Bailing capsule was a major product, achieving sales of over 3 billion yuan in 2019, but faced a decline in sales due to price reductions after being included in the medical insurance directory [17][18]. - Zhaoli Pharmaceutical, through acquisitions, has positioned itself in the Bailing market, with its Bailing tablet generating revenue of 2.02 billion yuan in 2023, down 21.23% from the previous year due to competitive pressures [18][19]. Group 3: Future Outlook - Zhaoli Pharmaceutical aims to grow its Bailing series into a 1 billion yuan product line, with expectations of increased revenue as the product gains market traction following its recent approval [19]. - As of December 16, 2023, Huadong Medicine's market capitalization was approximately 69.1 billion yuan, while Zhaoli Pharmaceutical's was around 11.9 billion yuan, indicating a significant disparity in market valuation [19].

Core Viewpoint - The patent dispute between two listed pharmaceutical companies, Huadong Medicine and Zhaoli Pharmaceutical, centers on the invention patent rights of fermented Cordyceps sinensis powder, which is a key ingredient in Huadong's previously exclusive product, Bailing Capsules [2][4][5]. Group 1: Legal Proceedings - Huadong Medicine's subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical, received a civil judgment from the Zhejiang High Court, which dismissed all of Huadong's claims regarding the patent dispute [2][8]. - The case involved a claim for approximately 1.1139 billion yuan, which increased by 10,600 yuan from the initial disclosure [2][7]. - Huadong Medicine plans to appeal to the Supreme People's Court following the unfavorable ruling [4][9]. Group 2: Market Impact - The dispute is significant as it affects the market for Bailing products, which has historically generated substantial revenue, with Bailing Capsules achieving sales exceeding 30 billion yuan in previous years [4][11]. - Following the approval of Zhaoli Pharmaceutical's Bailing Capsules as a same-name product in January 2024, the market dynamics shifted, leading to a near equal division of the Bailing product line between the two companies [4][13]. - Zhaoli Pharmaceutical's Bailing series, including Bailing Capsules and Bailing Tablets, reported a combined revenue of 1.88 billion yuan in 2024, with expectations for future growth as they aim to establish the series as a 1 billion yuan product [12][14]. Group 3: Financial Performance - Huadong Medicine's Bailing Capsules had sales of 34.86 billion yuan in 2019, but faced a decline due to price reductions after being included in the medical insurance directory, stabilizing around 18 billion yuan in 2022 [11]. - Zhaoli Pharmaceutical's Bailing Tablets generated 2.02 billion yuan in revenue in 2023, reflecting a 21.23% decline due to competitive pressures and pricing strategies [12].